top of page
>
>
Determine the better investment (in-house vs in-license) option for a small molecule drug
Client Problems
- A mid-side biotech company wanted to explore adding a small molecule inhibitor to a newly discovered target in their therapeutic area
- They wanted to determine the cost : benefit ratio of two options
- Develop the small molecule inhibitor in-house
- In-license a small molecule inhibitor from another company
What We Did
- We analyzed two investment options for the novel SM inhibitor
- We build an model to accurately determine the potential NPV and sales for the two investment options
- Included portfolio level and fundraising strategic considerations for each investment option
- Determined the impact of Loss of Exclusivity and the IP value in each scenario and ran a sensitivity analysis on the model.
Our Results And Insight
- Sales forecast & NPV for both scenarios
- Flexible powerful valuation tool. Includes real time sensitivity analysis
- Corporate Development Plan
- New Insights
See other case studies
Commercial Strategy case studies >
Central Nervous System case studies >
Service Areas Details
Commercial Strategy (Valuation, Business Development)
Therapeutic Areas Details
Central Nervous System (Parkinson's, ALS)
Featured Consultants
bottom of page